Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Iodine in food- and dietary supplement-composition databases.

Pehrsson PR, Patterson KY, Spungen JH, Wirtz MS, Andrews KW, Dwyer JT, Swanson CA.

Am J Clin Nutr. 2016 Sep;104 Suppl 3:868S-76S. doi: 10.3945/ajcn.115.110064. Epub 2016 Aug 17.

2.

Interlaboratory Trial for Measurement of Vitamin D and 25-Hydroxyvitamin D [25(OH)D] in Foods and a Dietary Supplement Using Liquid Chromatography-Mass Spectrometry.

Roseland JM, Patterson KY, Andrews KW, Phillips KM, Phillips MM, Pehrsson PR, Dufresne GL, Jakobsen J, Gusev PA, Savarala S, Nguyen QV, Makowski AJ, Scheuerell CR, Larouche GP, Wise SA, Harnly JM, Williams JR, Betz JM, Taylor CL.

J Agric Food Chem. 2016 Apr 27;64(16):3167-75. doi: 10.1021/acs.jafc.5b05016. Epub 2016 Apr 15.

3.

Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.

Cottrell ML, Prince HM, Allmon A, Mollan KR, Hudgens MG, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Patterson KB, Kashuba AD.

J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):498-506. doi: 10.1097/QAI.0000000000000996.

4.

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Hudgens MG, Wulff J, Patterson KB, Nelson JA, Kashuba AD.

J Infect Dis. 2016 Jul 1;214(1):55-64. doi: 10.1093/infdis/jiw077. Epub 2016 Feb 24.

5.

Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.

Dumond JB, Francis O, Cottrell M, Trezza C, Prince HM, Mollan K, Sykes C, Torrice C, White N, Malone S, Wang R, Van Dam C, Patterson KB, Hudgens MG, Sharpless NE, Forrest A.

Antivir Ther. 2016;21(5):441-5. doi: 10.3851/IMP3017. Epub 2016 Jan 5.

6.

No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.

Salem AH, Jones AK, Santini-Oliveira M, Taylor GP, Patterson KB, Nilius AM, Klein CE.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):400-8. doi: 10.1128/AAC.01197-15.

7.

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince HA, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, Elharrar V, Mayer KH, Patterson KB.

AIDS Res Hum Retroviruses. 2016 Jan;32(1):32-43. doi: 10.1089/AID.2015.0182. Epub 2015 Oct 15.

8.

Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.

Floris-Moore MA, Mollan K, Wilkin AM, Johnson MA, Kashuba AD, Wohl DA, Patterson KB, Francis O, Kronk C, Eron JJ.

Antivir Ther. 2016;21(1):55-64. doi: 10.3851/IMP2982. Epub 2015 Aug 11.

9.

Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.

Cottrell ML, Patterson KB, Prince HM, Jones A, White N, Wang R, Kashuba AD.

Antivir Ther. 2015;20(8):795-803. doi: 10.3851/IMP2968. Epub 2015 Jun 3.

10.

Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.

Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW; ACTG A5311 Study Team.

Antimicrob Agents Chemother. 2015;59(6):3399-405. doi: 10.1128/AAC.05128-14. Epub 2015 Mar 30.

11.

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team.

Clin Infect Dis. 2015 Jun 15;60(12):1842-51. doi: 10.1093/cid/civ193. Epub 2015 Mar 12.

12.

Models for predicting effective HIV chemoprevention in women.

Nicol MR, Emerson CW, Prince HM, Nelson JA, Fedoriw Y, Sykes C, Geller EJ, Patterson KB, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):369-76. doi: 10.1097/QAI.0000000000000472.

13.

Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.

Rahangdale L, De Paris K, Kashuba AD, Nelson JA, Cottrell M, Sykes C, Emerson C, Young SL, Stevens T, Patterson KB, Cohen MS.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):420-4. doi: 10.1097/QAI.0000000000000480.

14.

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum in: Ann Intern Med. 2014 Nov 4;161(9):680.

15.

"I should know better": the roles of relationships, spirituality, disclosure, stigma, and shame for older women living with HIV seeking support in the South.

Grodensky CA, Golin CE, Jones C, Mamo M, Dennis AC, Abernethy MG, Patterson KB.

J Assoc Nurses AIDS Care. 2015 Jan-Feb;26(1):12-23. doi: 10.1016/j.jana.2014.01.005. Epub 2014 Mar 12.

16.

Including food 25-hydroxyvitamin D in intake estimates may reduce the discrepancy between dietary and serum measures of vitamin D status.

Taylor CL, Patterson KY, Roseland JM, Wise SA, Merkel JM, Pehrsson PR, Yetley EA.

J Nutr. 2014 May;144(5):654-9. doi: 10.3945/jn.113.189811. Epub 2014 Mar 12.

17.

Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention.

Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, Mollan K, Mathews S, Kroetz DL, Kashuba AD.

J Clin Pharmacol. 2014 May;54(5):574-83. doi: 10.1002/jcph.248. Epub 2014 Jan 2.

18.

Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.

Patterson KB, Prince HA, Stevens T, Shaheen NJ, Dellon ES, Madanick RD, Jennings S, Cohen MS, Kashuba AD.

AIDS. 2013 Jun 1;27(9):1413-9. doi: 10.1097/QAD.0b013e32835f2b49.

19.

Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.

Greener BN, Patterson KB, Prince HM, Sykes CS, Adams JL, Dumond JB, Shaheen NJ, Madanick RD, Dellon ES, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):39-44. doi: 10.1097/QAI.0b013e31829ed7a4.

20.

Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.

Adams JL, Patterson KB, Prince HM, Sykes C, Greener BN, Dumond JB, Kashuba AD.

Antivir Ther. 2013;18(8):1005-13. doi: 10.3851/IMP2665. Epub 2013 Jul 31.

Supplemental Content

Loading ...
Support Center